Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Swift, A
1998.
Managing Infections.
p.
41.
Sabo, Janelle A
and
Abdel-Rahman, Susan M
2000.
Voriconazole: A New Triazole Antifungal.
Annals of Pharmacotherapy,
Vol. 34,
Issue. 9,
p.
1032.
Elewski, Be
and
Elmets, Ca
2000.
Drug‐induced photosensitivity with antimycotics.
Journal of the European Academy of Dermatology and Venereology,
Vol. 14,
Issue. 6,
p.
444.
Nenoff, P.
Kellermann, S.
Horn, L.‐C.
Keiner, S.
Bootz, F.
Schneider, S.
and
Haustein, U.‐F.
2001.
Case Report. Mycotic arteritis due to Aspergillus fumigatus in a diabetic with retrobulbar aspergillosis and mycotic meningitis.
Mycoses,
Vol. 44,
Issue. 9-10,
p.
407.
Fernandes, Yvens B.
Ramina, Ricardo
Borges, Guilherme
Queiroz, Luciano S.
Maldaun, Marcos V.C.
and
Maciel Jr., Jayme A.
2001.
Orbital apex syndrome due to aspergillosis: case report.
Arquivos de Neuro-Psiquiatria,
Vol. 59,
Issue. 3B,
p.
806.
Denning, D. W.
and
Griffiths, C. E. M.
2001.
Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
Clinical and Experimental Dermatology,
Vol. 26,
Issue. 8,
p.
648.
Safdar, Amar
Dommers, Jr., Martin P.
Talwani, Rohit
and
Thompson, Charlotte R.
2002.
Intracranial Perineural Extension of Invasive Mycosis: A Novel Mechanism of Disease Propagation byAspergillus fumigatus.
Clinical Infectious Diseases,
Vol. 35,
Issue. 5,
p.
e50.
Lazarus, Hillard M.
Blumer, Jeffrey L.
Yanovich, Saul
Schlamm, Haran
and
Romero, Alain
2002.
Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study.
The Journal of Clinical Pharmacology,
Vol. 42,
Issue. 4,
p.
395.
Cada, Dennis J
Levien, Terri
and
Baker, Danial E.
2002.
Voriconazole.
Hospital Pharmacy,
Vol. 37,
Issue. 10,
p.
1066.
Rubin, Adam I.
Bagheri, Bita
and
Scher, Richard K.
2002.
Six Novel Antimycotics.
American Journal of Clinical Dermatology,
Vol. 3,
Issue. 2,
p.
71.
Stratov, I.
Korman, T. M.
and
Johnson, P. D. R.
2003.
Management of Aspergillus Osteomyelitis: Report of Failure of Liposomal Amphotericin B and Response to Voriconazole in an Immunocompetent Host and Literature Review.
European Journal of Clinical Microbiology and Infectious Diseases,
Vol. 22,
Issue. 5,
p.
277.
Pearson, Margaret M
Rogers, P David
Cleary, John D
and
Chapman, Stanley W
2003.
Voriconazole: A New Triazole Antifungal Agent.
Annals of Pharmacotherapy,
Vol. 37,
Issue. 3,
p.
420.
Coste, André
Bretagne, Stéphane
and
Jankowski, Roger
2003.
Micosis rinosinusales.
EMC - Otorrinolaringología,
Vol. 32,
Issue. 3,
p.
1.
Boucher, Helen W
Groll, Andreas H
Chiou, Christine C
and
Walsh, Thomas J
2004.
Newer Systemic Antifungal Agents.
Drugs,
Vol. 64,
Issue. 18,
p.
1997.
Rubenstein, Melissa
Levy, Moise L.
and
Metry, Denise
2004.
Voriconazole‐Induced Retinoid‐Like Photosensitivity in Children.
Pediatric Dermatology,
Vol. 21,
Issue. 6,
p.
675.
Singh, Nina
and
Paterson, David L.
2005.
AspergillusInfections in Transplant Recipients.
Clinical Microbiology Reviews,
Vol. 18,
Issue. 1,
p.
44.
Coste, André
Bretagne, Stéphane
and
Jankowski, Roger
2006.
Mycoses rhinosinusiennes.
EMC - Oto-rhino-laryngologie,
Vol. 1,
Issue. 1,
p.
1.
Pinzer, T.
Reiß, M.
Bourquain, H.
Krishnan, K. G.
and
Schackert, G.
2006.
Primary aspergillosis of the sphenoid sinus with pituitary invasion – a rare differential diagnosis of sellar lesions.
Acta Neurochirurgica,
Vol. 148,
Issue. 10,
p.
1085.
Pem�n, Javier
Salavert, Miguel
Cant�n, Emilia
Jarque, Isidro
Rom�, Eva
Zaragoza, Rafael
Viudes, �ngel
and
Gobernado, Miguel
2006.
Voriconazole in the management of nosocomial invasive fungal infections.
Therapeutics and Clinical Risk Management,
Vol. 2,
Issue. 2,
p.
129.
McCarthy, K. L.
Playford, E. G.
Looke, D. F. M.
and
Whitby, M.
2007.
Severe Photosensitivity Causing Multifocal Squamous Cell Carcinomas Secondary to Prolonged Voriconazole Therapy.
Clinical Infectious Diseases,
Vol. 44,
Issue. 5,
p.
e55.